Tuberculosis: Latency and Reactivation

Tuberculosis is a major cause of death around the world, with most of the 1.5 million deaths per year attributable to the disease occurring in developing countries. This disease is caused by Mycobacterium tuberculosis , an acid-fast bacillus that is transmitted primarily via the respiratory route.

[1]  JoAnne L. Flynn,et al.  Effects of Tumor Necrosis Factor Alpha on Host Immune Response in Chronic Persistent Tuberculosis: Possible Role for Limiting Pathology , 2001, Infection and Immunity.

[2]  R. North,et al.  The Relative Importance of T Cell Subsets in Immunity and Immunopathology of Airborne Mycobacterium tuberculosis Infection in Mice , 2001, The Journal of experimental medicine.

[3]  JoAnne L. Flynn,et al.  Fate of Mycobacterium tuberculosis within Murine Dendritic Cells , 2001, Infection and Immunity.

[4]  I. Orme,et al.  Temporal and Spatial Arrangement of Lymphocytes within Lung Granulomas Induced by Aerosol Infection with Mycobacterium tuberculosis , 2001 .

[5]  P. Andersen,et al.  Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells , 2000, European journal of immunology.

[6]  Gilla Kaplan,et al.  Immunopathologic Effects of Tumor Necrosis Factor Alpha in Murine Mycobacterial Infection Are Dose Dependent , 2000, Infection and Immunity.

[7]  R. Hunter,et al.  Hypersusceptibility of A/J Mice to Tuberculosis is in Part Due to a Deficiency of the Fifth Complement Component (C5) , 2000, Scandinavian journal of immunology.

[8]  James C. Sacchettini,et al.  Persistence of Mycobacterium tuberculosis in macrophages and mice requires the glyoxylate shunt enzyme isocitrate lyase , 2000, Nature.

[9]  John Chan,et al.  Depletion of Cd4+ T Cells Causes Reactivation of Murine Persistent Tuberculosis despite Continued Expression of Interferon γ and Nitric Oxide Synthase 2 , 2000, The Journal of experimental medicine.

[10]  J. Flynn,et al.  Immune responses in tuberculosis. , 2000, Current opinion in immunology.

[11]  R. Hunter,et al.  Identification of viable and non-viable Mycobacterium tuberculosis in mouse organs by directed RT-PCR for antigen 85B mRNA. , 2000, Microbial pathogenesis.

[12]  N. Federspiel,et al.  Granuloma-specific expression of Mycobacterium virulence proteins from the glycine-rich PE-PGRS family. , 2000, Science.

[13]  I. Smith,et al.  Oxygenated mycolic acids are necessary for virulence of Mycobacterium tuberculosis in mice , 2000, Molecular microbiology.

[14]  M. Glickman,et al.  A novel mycolic acid cyclopropane synthetase is required for cording, persistence, and virulence of Mycobacterium tuberculosis. , 2000, Molecular cell.

[15]  C. Harding,et al.  Mycobacterium tuberculosis inhibits MHC class II antigen processing in murine bone marrow macrophages. , 1998, Cellular immunology.

[16]  P. Lipsky,et al.  Infliximab (chimeric anti-tumour necrosis factor α monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial , 1999, The Lancet.

[17]  David G. Russell,et al.  Characterization of Activity and Expression of Isocitrate Lyase in Mycobacterium avium andMycobacterium tuberculosis , 1999, Journal of bacteriology.

[18]  William R. Jacobs,et al.  Complex lipid determines tissue-specific replication of Mycobacterium tuberculosis in mice , 1999, Nature.

[19]  W. Bishai,et al.  Attenuation of virulence in Mycobacterium tuberculosis expressing a constitutively active iron repressor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[20]  B. Gicquel,et al.  Identification of a virulence gene cluster of Mycobacterium tuberculosis by signature‐tagged transposon mutagenesis , 1999, Molecular microbiology.

[21]  L. Ting,et al.  Mycobacterium tuberculosis inhibits IFN-gamma transcriptional responses without inhibiting activation of STAT1. , 1999, Journal of immunology.

[22]  J. Graham,et al.  Identification of Mycobacterium tuberculosis RNAs synthesized in response to phagocytosis by human macrophages by selective capture of transcribed sequences (SCOTS). , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  J. Flynn,et al.  Reactivation of Latent Tuberculosis: Variations on the Cornell Murine Model , 1999, Infection and Immunity.

[24]  R. Chaisson,et al.  Analysis of Rifapentine for Preventive Therapy in the Cornell Mouse Model of Latent Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[25]  D. Radzioch,et al.  Attenuation of MHC class II expression in macrophages infected with Mycobacterium bovis bacillus Calmette-Guérin involves class II transactivator and depends on the Nramp1 gene. , 1999, Journal of immunology.

[26]  Christopher Dye,et al.  Global burden of tuberculosis , 1999 .

[27]  C. Dye,et al.  Consensus statement. Global burden of tuberculosis: estimated incidence, prevalence, and mortality by country. WHO Global Surveillance and Monitoring Project. , 1999, JAMA.

[28]  J. Flynn,et al.  Early Emergence of CD8+ T Cells Primed for Production of Type 1 Cytokines in the Lungs of Mycobacterium tuberculosis-Infected Mice , 1999, Infection and Immunity.

[29]  K. Moelling,et al.  Therapy of tuberculosis in mice by DNA vaccination , 1999, Nature.

[30]  M. Olivier,et al.  TNF-alpha and IL-10 modulate the induction of apoptosis by virulent Mycobacterium tuberculosis in murine macrophages. , 1999, Journal of immunology.

[31]  J. Flynn,et al.  Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis. , 1999, Journal of immunology.

[32]  S. Furney,et al.  Metronidazole Therapy in Mice Infected with Tuberculosis , 1999, Antimicrobial Agents and Chemotherapy.

[33]  J. Sedgwick,et al.  Structural deficiencies in granuloma formation in TNF gene-targeted mice underlie the heightened susceptibility to aerosol Mycobacterium tuberculosis infection, which is not compensated for by lymphotoxin. , 1999, Journal of immunology.

[34]  J. Casanova,et al.  Novel human immunodeficiencies reveal the essential role of type-I cytokines in immunity to intracellular bacteria. , 1998, Immunology today.

[35]  N. Reiner,et al.  Attenuation of HLA-DR expression by mononuclear phagocytes infected with Mycobacterium tuberculosis is related to intracellular sequestration of immature class II heterodimers. , 1998, Journal of immunology.

[36]  P. Gounon,et al.  Attenuation of virulence by disruption of the Mycobacterium tuberculosis erp gene. , 1998, Science.

[37]  D. Mitchison,et al.  Metronidazole has no antibacterial effect in Cornell model murine tuberculosis. , 1998, The international journal of tuberculosis and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[38]  I. Smith,et al.  sigA is an essential gene in Mycobacterium smegmatis , 1998, Molecular microbiology.

[39]  B. Barrell,et al.  Deciphering the biology of Mycobacterium tuberculosis from the complete genome sequence , 1998, Nature.

[40]  J. Ho,et al.  Induction of in vitro human macrophage anti-Mycobacterium tuberculosis activity: requirement for IFN-gamma and primed lymphocytes. , 1998, Journal of immunology.

[41]  B. Gicquel,et al.  Genetic advances for studying Mycobacterium tuberculosis pathogenicity , 1998, Molecular microbiology.

[42]  J. Flynn,et al.  Effects of aminoguanidine on latent murine tuberculosis. , 1998, Journal of immunology.

[43]  J. Mudgett,et al.  Identification of nitric oxide synthase as a protective locus against tuberculosis. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[44]  Z. Toossi,et al.  In vitro restoration of T cell responses in tuberculosis and augmentation of monocyte effector function against Mycobacterium tuberculosis by natural inhibitors of transforming growth factor beta. , 1997, Proceedings of the National Academy of Sciences of the United States of America.

[45]  W. Bishai,et al.  Sigma factors of Mycobacterium tuberculosis. , 1997, Tubercle and lung disease : the official journal of the International Union against Tuberculosis and Lung Disease.

[46]  K. Rock,et al.  Major histocompatibility class I presentation of soluble antigen facilitated by Mycobacterium tuberculosis infection. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[47]  L. Wayne,et al.  An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of nonreplicating persistence , 1996, Infection and immunity.

[48]  Z. Toossi,et al.  Cross-modulation by transforming growth factor beta in human tuberculosis: suppression of antigen-driven blastogenesis and interferon gamma production. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[49]  Matthias Abend,et al.  Tuberculosis: Pathogenesis, Protection and Control , 1996, Nature Medicine.

[50]  W. Jacobs,et al.  Mutation of the principal sigma factor causes loss of virulence in a strain of the Mycobacterium tuberculosis complex. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[51]  C. Lowenstein,et al.  Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice. , 1995, Immunity.

[52]  C. Nathan,et al.  Altered responses to bacterial infection and endotoxic shock in mice lacking inducible nitric oxide synthase , 1995, Cell.

[53]  J. Kolls,et al.  Exacerbation of acute and chronic murine tuberculosis by administration of a tumor necrosis factor receptor-expressing adenovirus. , 1995, The Journal of infectious diseases.

[54]  K. Tanaka,et al.  Effects of nitric oxide synthase inhibitors on murine infection with Mycobacterium tuberculosis , 1995, Infection and immunity.

[55]  Z. Toossi,et al.  Enhancement of intracellular growth of Mycobacterium tuberculosis in human monocytes by transforming growth factor-beta 1. , 1994, The Journal of infectious diseases.

[56]  L. Wayne,et al.  Metronidazole is bactericidal to dormant cells of Mycobacterium tuberculosis , 1994, Antimicrobial Agents and Chemotherapy.

[57]  G. Rook,et al.  Pathogenesis of Pulmonary Tuberculosis: an Interplay of Tissue-Damaging and Macrophage-Activating Immune Responses—Dual Mechanisms That Control Bacillary Multiplication , 1994 .

[58]  B. Bloom,et al.  Tuberculosis Pathogenesis, Protection, and Control , 1994 .

[59]  R. Steinman,et al.  Presentation of mycobacterial antigens by human dendritic cells: lack of transfer from infected macrophages , 1993, Infection and immunity.

[60]  J. Flynn,et al.  An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection , 1993, The Journal of experimental medicine.

[61]  I. Orme,et al.  Disseminated tuberculosis in interferon gamma gene-disrupted mice , 1993, The Journal of experimental medicine.

[62]  A. Bradley,et al.  Multiple defects of immune cell function in mice with disrupted interferon-gamma genes. , 1993, Science.

[63]  J. Flynn,et al.  Major histocompatibility complex class I-restricted T cells are required for resistance to Mycobacterium tuberculosis infection. , 1992, Proceedings of the National Academy of Sciences of the United States of America.

[64]  B. Bloom,et al.  Killing of virulent Mycobacterium tuberculosis by reactive nitrogen intermediates produced by activated murine macrophages , 1992, The Journal of experimental medicine.

[65]  P. Randhawa,et al.  Lymphocyte subsets in granulomas of human tuberculosis: An in situ immunofluorescence study using monoclonal antibodies , 1990, Pathology.

[66]  V. Kindler,et al.  The inducing role of tumor necrosis factor in the development of bactericidal granulomas during BCG infection , 1989, Cell.

[67]  S. Vermund,et al.  A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. , 1989, The New England journal of medicine.

[68]  I. Orme.  A mouse model of the recrudescence of latent tuberculosis in the elderly. , 1988, The American review of respiratory disease.

[69]  A. Pugsley.  Molecular genetics in mycobacteria. , 1987, Microbiological sciences.

[70]  W. Stead,et al.  Does the risk of tuberculosis increase in old age? , 1983, The Journal of infectious diseases.

[71]  L G Wayne,et al.  Glyoxylate metabolism and adaptation of Mycobacterium tuberculosis to survival under anaerobic conditions , 1982, Infection and immunity.

[72]  K. Stýblo,et al.  Recent advances in epidemiological research in tuberculosis. , 1982, Advances in tuberculosis research. Fortschritte der Tuberkuloseforschung. Progres de l'exploration de la tuberculose.

[73]  L. Wayne,et al.  Synchronized replication of Mycobacterium tuberculosis , 1977, Infection and immunity.

[74]  L. G. Wayne.  Dynamics of submerged growth of Mycobacterium tuberculosis under aerobic and microaerophilic conditions. , 2015, The American review of respiratory disease.

[75]  T. Ramakrishnan,et al.  Effect of age on the enzymes of tricarboxylic acid and related cycles in Mycobacterium tuberculosis H37Rv. , 1973, The American review of respiratory disease.

[76]  W. Mcdermott,et al.  Microbial persistence. I. The capacity of tubercle bacilli to survive sterilization in mouse tissues. , 1966 .

[77]  W. Mcdermott,et al.  MICROBIAL PERSISTENCE : II. CHARACTERISTICS OF THE STERILE STATE OF TUBERCLE BACILLI , 1966 .

[78]  S. Grzybowski,et al.  THE CHALLENGE OF TUBERCULOSIS IN DECLINE. A STUDY BASED ON THE EPIDEMIOLOGY OF TUBERCULOSIS IN ONTARIO, CANADA. , 1964, The American review of respiratory disease.

[79]  R. Rees,et al.  Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. , 1961, British journal of experimental pathology.

[80]  W. Mcdermott,et al.  THE FATE OF MYCOBACTERIUM TUBERCULOSIS IN MOUSE TISSUES AS DETERMINED BY THE MICROBIAL ENUMERATION TECHNIQUE , 1956, The Journal of experimental medicine.

[81]  THE PERSISTENCE OF TUBERCULOUS INFECTION , 1934 .

[82]  Robertson He.  The Persistence of Tuberculous Infections , 1933 .

[83]  Opie,et al.  Tubercle Bacilli in Latent Tuberculous Lesions in Lung Tissue without Tuberculous Lesions , 1928 .